Navigation Links
BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana

Working with non-profit, faith-based and community organizations to

proactively get the job done

NEWARK, N.J., Aug. 22 /PRNewswire/ -- BioNeutral announced today the conclusion of an agreement with a non-profit organization to utilize its Ogiene(TM) FE technology to bring 10,000 mobile homes into full compliance so they can finally be safely used by those families so desperately in need of biohazard-free housing.

Dr. Andy Kielbania, Chief Scientist at BioNeutral, said, "All of our test data shows that Ogiene(TM) FE will be extremely effective in reducing and maintaining low levels of formaldehyde. We look forward to installing the first Ogiene(TM) FE systems in Louisiana mobile homes to bring relief to those who have endured so much suffering. Field test data will be carefully monitored and provided to the appropriate organizations."

Steve Browand, Managing Director, said, "We have authorized the human and financial resources to commence installation of our new Ogiene(TM) FE systems within the next few weeks. BioNeutral's staff will diligently work with non-profit and faith-based organizations to accelerate the availability of safe mobile homes and temporary dwellings which are currently unavailable due to formaldehyde contamination. The agreement contains special pricing which has been developed exclusively for this non-profit sector, making this a real life-saving solution to a serious problem. Our program will undoubtedly have a tremendous quality-of-life impact on the lives of over 100,000 affected families."

Visit to watch our Formaldehyde Videos.

About BioNeutral Laboratories Corporation

BioNeutral was organized in 2003 to commercialize a novel combinational chemistry-based technology that can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses and spores. The Ygiene(TM) and Ogiene(TM) formulations are "Green" and include natural and common ingredients which are found in baby products and the foods we eat. These widely used compounds are combined in unique ways to create enhanced results.

BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. The products include BioNeutralizers and ChemoNeutralizers. BioNeutralizers disinfect, decontaminate and sterilize. BioNeutral believes it has the broadest-based, fastest acting, most effective and safest antimicrobial known. This class of products has important applications for consumers, healthcare and the military. ChemoNeutralizers irreversibly bind chemical contaminant and toxin molecules and render them harmless. Product applications include industrial pollution and protection against chemical weapons of mass destruction.

Contact Information:

BioNeutral Laboratories Corporation USA

Dr. Andy Kielbania

Chief Scientist

Stephen J. Browand


Governmental Affairs

This release was issued through eReleases(TM). For more information, visit

SOURCE BioNeutral Laboratories Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
2. BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs
3. BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism
4. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
5. Lumidigm Signs Strategic Agreement with Methode Electronics : Automotive Supplier Invests in Biometric Component Development
6. Spherics, Inc. Assigns Assets to Joseph F. Finn, Jr., C.P.A.
7. Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract
8. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
9. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
10. Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System
11. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... ... 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for production, ... to serve as Chief Operating Officer. , Having joined InSphero in November ... and was promoted to Head of InSphero Diagnostics in 2014. There she has ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):